Market Closed -
Warsaw S.E.
09:25:52 02/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
0.59
PLN
|
+0.34%
|
|
-2.32%
|
+0.34%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
117.4
|
93.47
|
84.37
|
96.84
|
96.84
|
74.69
|
Enterprise Value (EV)
1 |
117.4
|
93.69
|
48.11
|
85.84
|
92.45
|
68.39
|
P/E ratio
|
-49.3
x
|
-3.48
x
|
-2.08
x
|
-7.65
x
|
60.5
x
|
-11.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.51
x
|
1.34
x
|
1.23
x
|
1.48
x
|
1.14
x
|
0.87
x
|
EV / Revenue
|
1.51
x
|
1.34
x
|
0.7
x
|
1.31
x
|
1.09
x
|
0.8
x
|
EV / EBITDA
|
-250
x
|
-71.6
x
|
11.2
x
|
-998
x
|
31.9
x
|
-48.3
x
|
EV / FCF
|
-22.7
x
|
-1.76
x
|
1.1
x
|
6.84
x
|
-19.4
x
|
12.9
x
|
FCF Yield
|
-4.41%
|
-56.8%
|
90.7%
|
14.6%
|
-5.16%
|
7.75%
|
Price to Book
|
0.91
x
|
0.84
x
|
1.17
x
|
1.55
x
|
1.49
x
|
1.22
x
|
Nbr of stocks (in thousands)
|
77,205
|
84,205
|
84,205
|
84,205
|
84,205
|
84,205
|
Reference price
2 |
1.520
|
1.110
|
1.002
|
1.150
|
1.150
|
0.8870
|
Announcement Date
|
27/04/18
|
13/04/19
|
24/04/20
|
23/04/21
|
22/04/22
|
30/03/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
77.58
|
69.79
|
68.41
|
65.29
|
84.73
|
85.36
|
EBITDA
1 |
-0.47
|
-1.308
|
4.288
|
-0.086
|
2.902
|
-1.416
|
EBIT
1 |
-4.869
|
-5.663
|
1.702
|
-2.981
|
0.092
|
-4.376
|
Operating Margin
|
-6.28%
|
-8.11%
|
2.49%
|
-4.57%
|
0.11%
|
-5.13%
|
Earnings before Tax (EBT)
1 |
-1.901
|
-24.87
|
-41.13
|
-12.7
|
1.757
|
-6.242
|
Net income
1 |
-2.021
|
-24.98
|
-40.54
|
-12.66
|
1.635
|
-6.568
|
Net margin
|
-2.6%
|
-35.79%
|
-59.25%
|
-19.4%
|
1.93%
|
-7.69%
|
EPS
2 |
-0.0309
|
-0.3187
|
-0.4814
|
-0.1504
|
0.0190
|
-0.0780
|
Free Cash Flow
1 |
-5.179
|
-53.21
|
43.64
|
12.56
|
-4.766
|
5.299
|
FCF margin
|
-6.67%
|
-76.24%
|
63.8%
|
19.23%
|
-5.63%
|
6.21%
|
FCF Conversion (EBITDA)
|
-
|
-
|
1,017.79%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/04/18
|
13/04/19
|
24/04/20
|
23/04/21
|
22/04/22
|
30/03/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
0.09
|
0.23
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
36.3
|
11
|
4.38
|
6.3
|
Leverage (Debt/EBITDA)
|
-0.1979
x
|
-0.1728
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-5.18
|
-53.2
|
43.6
|
12.6
|
-4.77
|
5.3
|
ROE (net income / shareholders' equity)
|
-1.57%
|
-19.6%
|
-42.6%
|
-18.7%
|
2.6%
|
-10.5%
|
ROA (Net income/ Total Assets)
|
-1.68%
|
-2.11%
|
0.81%
|
-1.9%
|
0.06%
|
-2.71%
|
Assets
1 |
120.6
|
1,186
|
-5,030
|
666.9
|
2,753
|
242.1
|
Book Value Per Share
2 |
1.670
|
1.330
|
0.8600
|
0.7400
|
0.7700
|
0.7300
|
Cash Flow per Share
2 |
0.0300
|
0.0300
|
0.0900
|
0.1200
|
0.0300
|
0.0200
|
Capex
1 |
1.29
|
1.13
|
1.4
|
0.18
|
4.45
|
2.48
|
Capex / Sales
|
1.66%
|
1.62%
|
2.04%
|
0.28%
|
5.25%
|
2.91%
|
Announcement Date
|
27/04/18
|
13/04/19
|
24/04/20
|
23/04/21
|
22/04/22
|
30/03/23
|
|
1st Jan change
|
Capi.
|
---|
| +0.34% | 12.37M | | -1.89% | 12.56B | | -9.59% | 7.68B | | -1.31% | 5.29B | | +21.82% | 5.24B | | +0.02% | 4.57B | | -50.89% | 3.29B | | +6.42% | 2.6B | | -10.02% | 2.2B | | -8.29% | 1.79B |
Diagnostic & Testing Substances
|